Oral Presentation given to the European Society of Medical Oncology - Immuno-Oncology Congress 2024 (ESMO-IO 2024)

Phase I/II trial evaluating the innovative therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients with untreated Stage IV Non-Small Cell Lung Cancer

J. Vansteenkiste, K. Cuppens, I. Demedts, F. Borm, B. Biesma, M. Pérol, W. Theelen, E. Wauters, B. Colinet, C. Van Kerckhove, E. Buchmeier, F. Althoff, E. Pons-Tostivint, S. Derijcke, D. Moro-Sibilot, A. Sibille, J. Plumas, S. Adriaenssens, F. Cantero, M. Skrzypski;

Presented December 12, 2024

/sites/default/files/images/2412PDC-LUNG-101-slides-ESMO-IO2024-final.pdf

Oral Presentation given to the American Association for Cancer Research (AACR) Annual Meeting 2024

Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients with Stage IV NSCLC

W. Theelen, M. Perol, K. Cuppens, I. Demedts, F. Borm, B. Biesma, E. Wauters, B. Colinet, E.-L. Buchmeier, F. Althoff, E. Pons-Tostivint, C. Van de Kerkhove, D. Moro-Sibilot, A. Sibille, S. Derijcke, M. Skrzypski, J. Plumas, B. De Vos, C. Debruyne, F. Cantero, S. Adriaenssens, F. Renard, J. Vansteenkiste;

Presented April 7, 2024

/Check the document

Poster presented to AACR Annual Meeting 2024

PDC*lung01: An innovative therapeutic cancer vaccine induces specific immune responses in combination with anti-PD-1 treatment in patients with non-small cell lung cancer

J. Plumas, A. Sibille, I. Demedts, E. Pons-Tostivint, C. Van de Kerkhove, S. Derijcke, W. Theelen, B. Biesma, F. Borm, E. Wauters, M. Collodoro, K. Al Badawy, C. Duchayne, C. Debruyne, B. De Vos, B. Colinet, D. Moro-Sibilot, M. Perol, E. Buchmeier, M. Skrzypski, K. Cuppens, J. Vansteenkiste

Presented April 7, 2024

/Check the document

Oral Presentation given to the 49th annual meeting of the Korean Cancer Association & 9th international Cancer Conference

A new plasmacytoid dendritic cell-based vaccine in combination with anti-PD-1 expands tumor-specific CD8+ T cells of lung cancer patients

S-E. Kim, D. Hannani, E. Leplus, D. Laurin, B. Caulier, C. Aspord, N. Madelon, E. Bourova-Flin, C. Brambilla, E. Brambilla, A-C. Toffart, K. Laulagnier, L. Chaperot, J. Plumas

Presented June 15, 2023

PLUMAS J_KCA 2023.pdf

Poster presented to 20th CIMT Annual Meeting 

Induction of circulating antitumor specific CD8+ T cells in patients with non-small cell lung cancer treated with an allogeneic plasmacytoid dendritic-cell based cancer vaccine with or without anti- PD-1 treatment
S. Michel, I. Demedts, A. Sibille, E. Pons-Tostivint, C. Van de Kerkhove, S. Derijcke, M. Collodoro, K. Al Badawy, C. Duchayne, C. Debruyne, M. Perol, E.-L. Buchmeier, K. Cuppens, J. Vansteenkiste, J. Plumas

Presented May 5, 2023

Check the document
 

Poster presented to ESMO Iummuno-Oncology Congress 2022 

The therapeutic cancer vaccine PDC*lung01 induces immune responses with or without anti- PD-1 treatment in patients with non-small cell lung cancer
A. Sibille, J. Plumas, I. Demedts, E. Pons-Tostivint, C. Van de Kerkhove, S. Derijcke, M. Collodoro, K. Al Badawy, C. Duchayne, C. Debruyne, M. Pérol, E. Buchmeier, K. Cuppens, J. Vansteenkiste

Presented December 8, 2022
Check the document

Poster presented to ESMO 2022 Annual Meeting

Open-label, dose-escalation, phase I/II study to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-Programmed Death-1 (PD-1) treatment in patients with non-small-cell lung cancer (NSCLC).
J. Vansteenkiste, I. Demedts, E. Pons-Tostivint, B. Biesma, F. Borm, B. Colinet, K. Cuppens, S. Derijcke, L. Greillier, J. Jurgens, D. Moro-Sibilot, M. Pérol, M. Sebastian, M. Skrzypski, W. Theelen, C. Van De Kerkhove, M. Collodoro, J. Plumas, C. Debruyne, A. Sibille

Presented September 12, 2022
Check the document

eTalk given to the 18th CIMT Annual Meeting

Priming and expansion of functional antitumor T-cells in melanoma patients: results of phase I clinical trial with GeniusVac-Mel4, an innovative cancer vaccine based on a plasmacytoid dendritic cell line.
J. Charles, L. Chaperot, D. Hannani, J. Bruder Costa, I. Templier, S. Trabelsi, H. Gil, A. Moisan, V. Persoons, H. Hegelhofer, E. Schir, J.-L. Quesada, C. Mendoza, C. Aspord, O. Manches, P. Coulie, A. Khammari, B. Dreno, M.-T. Leccia, J. Plumas.

Presented: May 10-12, 2022
Check the document

eTalk given to the 18th CIMT Annual Meeting

The retroviral engineering of a human plasmacytoid dendritic cell-based vaccine allowed the priming and expansion of multispecific viral and tumor antigen-specific T-cells in multiple HLA contexts.
K. Lenogue, A. Walencik, K. Laulagnier, J.-P. Molens, H. Benlalam, B. Dreno, P. Coulie, M. Pule, L. Chaperot, J. Plumas

Presented: May 10-12, 2022
Check the document
 

Poster presented to ESMO Iummuno-Oncology Congress 2022 

The therapeutic cancer vaccine PDC*lung01 induces immune responses with or without anti- PD-1 treatment in patients with non-small cell lung cancer
A. Sibille, J. Plumas, I. Demedts, E. Pons-Tostivint, C. Van de Kerkhove, S. Derijcke, M. Collodoro, K. Al Badawy, C. Duchayne, C. Debruyne, M. Pérol, E. Buchmeier, K. Cuppens, J. Vansteenkiste

Presented December 8, 2022
Check the document

Poster presented to ESMO 2022 Annual Meeting

Open-label, dose-escalation, phase I/II study to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-Programmed Death-1 (PD-1) treatment in patients with non-small-cell lung cancer (NSCLC).
J. Vansteenkiste, I. Demedts, E. Pons-Tostivint, B. Biesma, F. Borm, B. Colinet, K. Cuppens, S. Derijcke, L. Greillier, J. Jurgens, D. Moro-Sibilot, M. Pérol, M. Sebastian, M. Skrzypski, W. Theelen, C. Van De Kerkhove, M. Collodoro, J. Plumas, C. Debruyne, A. Sibille

Presented September 12, 2022
Check the document

eTalk given to the 18th CIMT Annual Meeting

Priming and expansion of functional antitumor T-cells in melanoma patients: results of phase I clinical trial with GeniusVac-Mel4, an innovative cancer vaccine based on a plasmacytoid dendritic cell line.
J. Charles, L. Chaperot, D. Hannani, J. Bruder Costa, I. Templier, S. Trabelsi, H. Gil, A. Moisan, V. Persoons, H. Hegelhofer, E. Schir, J.-L. Quesada, C. Mendoza, C. Aspord, O. Manches, P. Coulie, A. Khammari, B. Dreno, M.-T. Leccia, J. Plumas.

Presented: May 10-12, 2022
Check the document

eTalk given to the 18th CIMT Annual Meeting

The retroviral engineering of a human plasmacytoid dendritic cell-based vaccine allowed the priming and expansion of multispecific viral and tumor antigen-specific T-cells in multiple HLA contexts.
K. Lenogue, A. Walencik, K. Laulagnier, J.-P. Molens, H. Benlalam, B. Dreno, P. Coulie, M. Pule, L. Chaperot, J. Plumas

Presented: May 10-12, 2022
Check the document

Poster presented to European Lung Cancer Virtual Congress (ELCC 2021 Virtual)

An open-label, dose escalation, Phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-Programmed Death-1 (PD-1) treatment in patients with Non-small cell lung cancer (NSCLC).
J. Bennouna, A. Sibille, C. Debruyne, B. Colinet, I. Demedts, S. Derijcke, L. Greillier, J. Jurgens, H. Lena, D. Moro-Sibilot, M. Pérol, X. Quantin, N. Reinmuth, M. Sebastian, M. Genin, J. Plumas, J. Vansteenkiste

Presented: March 25 – 27, 2021
Check the document

Poster presented to ESMO Immuno-Oncology Congress 2017

Priming and expansion of neo-antigen specific-T cells thanks to an off-the-self cell-based drug product.
Plumas J, De Sousa Alves PM, Leplus E, Chaperot L, Hannani D

December 7-10, 2017
Check the document